KORONER YURAK KASALLIGINI DAVOLASHDA BIORESORBLANADIGAN QON TOMIR STENTLARI VA DORI VOSITALARINI YUTUVCHI STENTLAR: META-TAHLIL
Keywords:
bioresorblanuvchi stent, dori bilan qoplangan stent, yurak ishemik kasalligi, tromboz, revaskulyarizatsiya, meta-tahlil, perkutan koronar intervensiya, restenoz.Abstract
Ushbu tadqiqotning maqsadi — yurak ishemik kasalligida bioresorblanuvchi tomir stentlari (BVS) va dori bilan qoplangan stentlar (DES) ning klinik samaradorligi va xavfsizligini taqqoslab baholashdan iborat. Meta-tahlil PubMed, EMBASE, Springer va Wiley-Blackwell kabi xalqaro ma’lumotlar bazalaridan olingan randomizatsiyalangan nazoratli tadqiqotlar asosida o‘tkazildi. Tahlilga jami 6 383 nafar bemorni o‘z ichiga olgan 10 ta tadqiqot kiritildi.Natijalar shuni ko‘rsatdiki, BVS bilan davolangan bemorlarda maqsadli lezyon yetishmovchiligi, stent trombozi va yurak o‘limi ko‘rsatkichlari DES bilan davolangan bemorlarga nisbatan sezilarli darajada yuqori bo‘lgan. Aksincha, DES klinik natijalarning barqarorroq bo‘lishini ta’minlab, koronar qon oqimini tiklashda yuqori samaradorlikni ko‘rsatdi. Bundan tashqari, DES qayta revaskulyarizatsiya amaliyotlari sonining kamligi va uzoq muddatli tomir o‘tkazuvchanligining yaxshilanishi bilan bog‘liq bo‘ldi.
Xulosa qilib aytganda, hozirgi vaqtda DES yurak ishemik kasalligini davolashda xavfsizroq va ishonchliroq strategiya hisoblanadi. Biroq, BVS texnologiyasi rivojlanishda davom etmoqda va kelajakda uning klinik qo‘llanilishi hamda xavfsizlik ko‘rsatkichlari yanada yaxshilanishi mumkin.
References
Arturo G, et al. Successful treatment of recurrent carotid in-stent restenosis and drug-eluting balloon failure with a coronary bioresorbable vascular scaffold: a case report. Int J Surg Case Rep. 2016;21:78–82. doi: 10.1016/j.ijscr.2016.02.035.
Chan W, et al. Complex coronary artery bifurcation treatment utilizing everolimus-eluting bioresorbable vascular scaffolds and optical coherence tomography. Coron Artery Dis. 2014;25(7):629–631. doi: 10.1097/MCA.0000000000000141.
Dalos D, et al. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. BMC Cardiovasc Disord. 2016;16(1):104. doi: 10.1186/s12872-016-0296-1.
Dudek D, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2012;7(9):1060–1061. doi: 10.4244/EIJV7I9A168.
Nef H, et al. German-Austrian ABSORB RegIstRy (GABI-R) Cardiovasc Revasc Med. 2016;17(1):34–37. doi: 10.1016/j.carrev.2015.09.002.
Ielasi A, Tespili M. Current and future perspectives on drug-eluting bioresorbable coronary scaffolds. Futur Cardiol. 2014;10(3):409–420. doi: 10.2217/fca.14.14.
Kimura T, et al. A randomized trial evaluating everolimus-eluting absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332–3342. doi: 10.1093/eurheartj/ehv435
Abizaid AMP, et al. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve Novolimus-eluting Bioresorbable coronary scaffold system for the treatment of single De novo coronary lesions. J Am Coll Cardiol Intv. 2016;9(6):565–574. doi: 10.1016/j.jcin.2015.12.004.
Brugaletta S, et al. Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging. 2012;28(6):1307–1314. doi: 10.1007/s10554-011-9981-4.
Ellis SG, et al. Everolimus-eluting Bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):1905–1915. doi: 10.1056/NEJMoa1509038. [DOI] [PubMed] [Google Scholar]





